NL-OMON46183已完成不适用
BIOTRONIK - Safety and clinical performance of the self-expanding transcatheter BIOVALVE prosthesis in subjects with severe symptomatic calcified aortic valve stenosis suitable for transfemoral transcatheter aortic valve implantation (TAVI) - C1205 BIOVALVE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- BIOTRONIK AG
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. The subject is >=65 years
- •2. The subject has provided written informed consent
- •3. Subject is willing to participate in the clinical investigation and to comply with all of the study procedures and follow-up visits
- •4. NHYA class >=II
- •5. High surgical risk: Logistic EuroSCORE-I >=20% (or equivalence of EuroSCORE-II) or STS score >=10% or co-morbidity judged by the heart team (consisting of at least one interventional cardiologist and one cardiac surgeon) to pose an absolute or relative contraindication for conventional aortic valve replacement according to VARC-2
- •6. Severe symptomatic calcific aortic valve stenosis characterized by mean aortic gradient >40 mm Hg or peak jet velocity >4.0 m/s or effective orifice area (EOA) of <1.0 cm2 (<0.6 cm2/m2 body surface area)
- •7. Annulus diameter as determined by multi-slice computed tomography (MSCT) from 20-26 mm
排除标准
- •1. Trans-esophageal echocardiogram (TEE) is contraindicated
- •2. Congenital bicuspid or unicuspid valve
- •3. Left ventricular outflow tract (LVOT) obstruction such as hypertrophic obstructive cardio myopathy (HOCM) or subject presenting with systolic anterior motion (SAM). Evidence of intra cardiac mass, thrombus or vegetation
- •4. Transfemoral access vessel characteristics that would preclude safe placement of a 18 French sheath
- •5. Vessel and/or anatomical characteristics that would preclude safe delivery of the BIOVALVE prosthesis to the ascending aorta and/or placement of the prosthesis
- •6. Anatomical restrictions such as shallow sinuses with heavily calcified leaflets, low height of coronary ostia, extreme tortuosity of the aortic arch, thoracic (TAA) or abdominal (AAA) aortic aneurysm, presence of endovascular stent graft
- •7. Severe mitral regurgitation grade >3
- •8. Severe mitral stenosis
- •9. Prosthetic mitral valve
- •10. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%
- •11. Hemodynamic instability
- •12. Percutaneous coronary intervention (PCI) within 30 days prior to index procedure and / or planned PCI during index procedure
- •13. Renal insufficiency (creatinine >2.5 mg/dl) or subject under dialysis and/or renal replacement therapy
- •14. Any cerebrovascular event or transient ischemic attack (TIA) within 180 days prior to TAVI procedure
- •15. Evidence of acute myocardial infarction (defined as >=2 fold CK level or in absence of CK a >=3 fold CKMB level above the upper range limit within <=30 days prior to TAVI procedure)
- •16. Blood dyscrasia defined as: leucopenia (WBC <1000 mm³), thrombocytopenia (platelet count <50*000 cells/mm³), history of bleeding diathesis requiring blood transfusion
- •17. Ongoing sepsis or suspected active endocarditis
- •18. Active peptic ulcer or gastrointestinal bleeding within last 3 months that would preclude anticoagulation
- •19. Subject refuses blood transfusion
- •20. Known hypersensitivity to, or contraindication to nitinol, anticoagulation/antiplatelet regimes, any other medications required for the procedure or post-procedure as determined by the heart team, or sensitivity to contrast media which cannot be adequately pre-medicated
- •21. Need for emergency TAVI intervention, or other medical, social, or psychological conditions that in the opinion of the heart team precludes the subjects from appropriate consent or adherence to protocol required follow-up exams
- •22. Expectation that subject will not improve despite treatment of aortic stenosis
- •23. Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbidities
- •24. Severe pulmonary hypertension (> 60 mm Hg assessed by continuous wave Doppler, TTE) or clinical signs of acute severe right ventricular dysfunction
- •25. Currently participating in another investigational drug or device study where primary endpoint has not been reached yet
研究者
相似试验
招募中
不适用
BIOTRONIK - Safety and Clinical Performance of the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-Icoronary stenosis- narrowing of the vessels (arteries) wich supply the hear with blood10011082NL-OMON52481BIOTRONIK AG12
招募中
不适用
BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-IIcoronary stenosisnarrowing of the vessels (arteries) which supply the heart with blood10011082NL-OMON46947Biotronik20
已完成
不适用
BIOTRONIKS-Safety and Clinical Performance of the First Drug-Eluting Generation Absorbable Metal Stent In Patients with de Novo Lesions in Native Coronary Arteries (BIOSOLVE-I study)NL-OMON56825Biotronik AG10
进行中（未招募）
2 期
To Study the safety and efficacy of drug releasing Orsiro Cardiac stent in patients with Coronary Artery DiseasesCTRI/2011/07/001928BIOTRONIK AG120
已完成
4 期
Biomodulina T - IM- covid-19 - older adultos - Phase IV clinical trialPrevention of infections, including covid-19Covid-19SARS-CoV2Disease PreventionAgingCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000310Centro Nacional de Biopreparados (BioCen)